Jiuzhitang (000989) Fundamentals 2026 — P/E 28.8x, Revenue Analysis | SniperIQ
Jiuzhitang (000989) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥7.7B, trading at ¥9.08 on the SHZ. This SniperIQ fundamentals page covers Jiuzhitang's valuation (P/E 28.8x, P/B 2.0x), profitability (net margin 11.3%), revenue (¥2.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jiuzhitang's market cap?
Jiuzhitang (000989) has a market capitalization of approximately ¥7.7B, trading at ¥9.08 on the SHZ. Market cap moves with the live share price.
What is Jiuzhitang's P/E ratio?
Jiuzhitang's trailing twelve-month P/E ratio is 28.8x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jiuzhitang?
Jiuzhitang runs a net profit margin of 11.3%, a gross margin of 59.6%, and an operating margin of 15.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jiuzhitang generate?
Jiuzhitang reported revenue of ¥2.2B for fiscal year 2025, with net income of ¥223M and earnings per share (EPS) of 0.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jiuzhitang pay a dividend?
Jiuzhitang offers a trailing dividend yield of about 3.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Jiuzhitang financially healthy?
Jiuzhitang carries a debt-to-equity ratio of 0.02x and a current ratio of 2.40x, with a market beta of 0.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jiuzhitang a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jiuzhitang (000989) the key facts are: market cap ¥7.7B, P/E 28.8x, revenue ¥2.2B, 52-week range 7.4-12.93. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jiuzhitang's full fundamentals live
Get Jiuzhitang's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.